Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Erectile Dysfunction Class Labeling Does Not Assert Causal Link To Vision Loss

This article was originally published in The Pink Sheet Daily

Executive Summary

Labeling revisions for Viagra, Levitra and Cialis will add information about NAION adverse events, but states that “it is not possible to determine whether these events are related directly to the use of PDE5 inhibitors or to other factors.”

You may also be interested in...



FDA Endpoint Development For Pediatric Pulmonary Arterial Hypertension Focuses On Pfizer's Revatio

The standard exercise test is a problem for many pediatric patients, and FDA's Cardiovascular and Renal Drugs Advisory Committee will assess alternatives.

FDA Endpoint Development For Pediatric Pulmonary Arterial Hypertension Focuses On Pfizer's Revatio

The standard exercise test is a problem for many pediatric patients, and FDA's Cardiovascular and Renal Drugs Advisory Committee will assess alternatives.

ED Drug Labeling Revised For Potential Risk Of Hearing Loss

FDA identifies 29 postmarketing reports of sudden hearing loss in patients using PDE 5 inhibitors, including Cialis, Levitra and Viagra.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS062688

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel